University of Texas MD Anderson Cancer Center, Theraclone, OncoResponse deal

MD Anderson and Theraclone jointly launched cancer immunotherapy company OncoResponse. The newco closed a $9.5 million series A round co-led by MD Anderson. OncoResponse licensed Theraclone’s I-STAR antibody discovery platform to identify antibodies from exceptional responders to immunotherapy. MD Anderson will provide the company with samples and physiologic, prognostic and genotypic data from exceptional responders. ...